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1. General Part 
1.1 Introduction 
1.1.1 Diphenylethylamines 
The consumption of drugs has ever been part of human behavior. Plants and fungi with 
their large spectrum of active constituents have been either used to cure illness or 
abused to modulate body functions. In relation to that, one may think of hallucinogenic 
shamanic rituals, central nervous system (CNS) stimulation of caffeine (in Coffea 
Arabica) or ephedrine (in Ephedra sinica), but also the variety of effects produced by 
opium (in Papaver somniferum). With the ongoing scientific research new possibilities 
came up. The ingredients of plants and fungi were analyzed and tested for 
pharmacological effects. From that knowledge, classes of drugs were chemically 
synthesized in order to find new drugs for medical usage. A phenethylamine derivative 
with sympathomimetic effects (3,4-methylenedioxymethamphetamine, MDMA) was 
invented in 1912 by Merck Industries. It could have been used as an appetite 
suppressant but has never been marketed due to e.g. vascular side effects.1 In spite of 
that, it is misused as an entactogenic CNS stimulating, controlled drug, known as 
Ecstasy.2 So the stimulating and also cardiovascular effects of phenylethylamines have 
already been known for over a hundred years. Due to these pharmacological properties, 
diphenylethylamines were further investigated in the early 1940’s in order to find new 
therapeutic drugs with fewer side effects. The chemical structures of such 
diphenylethylamines are depicted in Fig. 1. Tainter et al. studied 1,2-diphenylethylamine 
(DPEA) and several of its derivatives for CNS stimulation,3 while Dodds et al. tested this 
compound class for its analgesic effects.4 Approximately 20 years later, receptor 
binding and nuclear magnetic resonance (NMR) studies were conducted by Sasaki et 
al.5 According to these findings, the (1R)-N,N-dimethyl-1,2-diphenylethanamine 
(lefetamine, Fig. 1c) was marketed as an opioid-like analgesic (Santenol, L-SPA) in 
Japan. Although first signs of withdrawal symptoms have been recorded,6 it was 
marketed in the 1980’s in Italy, but has later been scheduled due to dependency and 
withdrawal.7-10 The core structure stayed interesting for the development of new 
designer drugs: In 2008, N-ethyl-1,2-diphenylethylamine (NEDPA, Fig. 1a) and N-iso-
propyl-1,2-diphenylethylamine (NPDPA, Fig. 1b) were confiscated by the German 
police. In Sweden and Japan 1-(1,2-diphenylethyl)piperidine (diphenidine, Fig. 1d) has 
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been associated with drug induced intoxications. Due to that, several studies including 
synthesis, analysis, receptor binding and metabolism have been conducted for 
characterization of these compounds.11-15 In many countries, such structurally similar 
drugs, often called “legal highs” or “research chemicals”, are not scheduled but may 
nevertheless lead to intoxications of drug abusers. In recent years more and more of 
such chemically derived compounds from various known drug classes have been 
recognized in order to circumvent the law.  
 
 
 a   b   c   d 
Fig. 1: NEDPA (a), NPDPA (b), lefetamine (c), diphenidine (d) 
 
1.1.2 Pharmacology 
Phenethylamines influence the signal transduction at (nor-)adrenergic, serotonergic, 
and dopaminergic receptors by inhibition of the transmitter reuptake. So, 
neurotransmitters stay in the synaptic cleft instead of being reabsorbed to presynapses, 
and can steadily bind to their receptors. This is the reason for the CNS stimulating 
effects and for tachyphylaxis, but maybe also for neurotoxicity.2 According to the 
chemical structure, diphenylethylamines are also influencing the signal transduction. 
Additional to the CNS stimulation, effects such as bronchodilatation, hypertension, 
tachyphylaxis comparable to amphetamine have been described.3,5  
Dodds et al. investigated the analgesic effects of diphenylethylamines according to the 
similarity to morphine and codeine (phenanthrene core)16,17 Typical opioid effects were 
recorded: depression of righting reflex in mice, hyperexcitability, miosis, increased blood 
sugar levels, and nausea in cats. DPEA showed pain relieving properties in patients.  
Pharmacologically, lefetamine was tested in the 1960’s in Japan, both the racemic 
compound and the enantiomers separately. Especially the L-isomer showed analgesic, 
antitussive, antipyretic, hypertensive, anticholinergic, vasoconstrictive, and local 
anesthetic effects. Furthermore, blood sugar was increased, barbiturate effects were 
3 
intensified and an inhibition of monoaminoxidase (MAO) was observed.18 These results 
were further confirmed 20 years later by Italian working groups: Janiri et al. tested 
lefetamine after neocortical application to rats and reported opioid agonism and 
glutamate antagonism. Also the opioid and CNS stimulating effects in patients were 
published.9,10 Afterwards, they tested lefetamine in order to reduce withdrawal 
symptoms with low effects compared to buprenorphine and clonidine.8 De Montis et al. 
confirmed the opiate activity by the fact that naloxone pretreatment abolished the 
described effects. Further in vitro investigations showed that lefetamine displaced opioid 
receptor agonists from their binding site.7 Diphenidine was shown to act as NMDA 
receptor blockers similar to ketamine, a therapeutically used narcotic also known as a 
drug of abuse.13,15,19 Also DPEA, which was already known to antagonize glutamate 
receptors as described above, and new derivatives of diphenidine were tested 
substrates.  
In summary, diphenylethylamines mainly showed CNS stimulating and opioid effects in 
vitro and in vivo. 
 
1.1.3 Metabolism 
After absorption, in most cases a drug needs to be metabolized to detoxify it, make it 
unlikely to be reabsorbed, clearable from blood system, and pharmacologically 
ineffective. Enzymes are responsible for these so-called biotransformations. A huge 
amount of them is located in the liver, but also in kidneys, gastrointestinal tract, skin, 
and bronchia. Hydrophilicity is often enhanced and so the substance can be excreted 
via urine, the most important way of excretion besides feces or exhaling. 
Phase I metabolism represents the modification via oxidation, reduction, or hydrolysis. 
For example, hydroxy groups can be introduced into a molecule by an enzyme class 
called oxygenases. Monooxygenases, a subset of oxygenases, transfer NAD(P)H or 
FAD-dependent one oxygen atom into a molecule. This reaction is necessary in 
different metabolism steps: oxidation of a carbon-hydrogen bond to an alcohol, 
epoxidation of double bindings, or aromatic hydroxylations. Alcohols are reduced to 
corresponding aldehydes or ketones. So, phase I metabolism leads to functionalized 
and more hydrophilic compounds. 
Monooxygenation and also reduction are often conducted by the hemoprotein group of 
cytochrome P450 (CYP). The name arose from the absorption band at 450 nm.20 The 
CYPs are sorted by their amino acid sequence, divided into three subgroups, according 
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to their homology: An Arabic number at first titles the family, followed by a letter that 
defines the subfamily, and at last an Arabic number again for the member of subfamily. 
CYP3A4, the most important example for drug metabolism, is the fourth member of 
subfamily A in family three.21,22 Currently, 18 CYP families, 43 subfamilies and 57 
members of the subfamilies are known.23 In humans, the greatest amount of CYPs is 
located in liver, but also in intestine, lung and brain. As they are part of membranes, 
liver preparations such as S9 or microsomes contain a comparable spectrum of the 
naturally occurring composition. As described above, commercially available cell 
systems can be used for in vitro studies.24 To check for the involvement of a single 
enzyme in this compartment, the others can be blocked with known inhibitors,25 and co-
substrates of other enzyme reactions are omitted. But apart from those cell systems, 
CYP isozymes can be heterologously cDNA-expressed in bacteria or yeast for 
example.26 This bears the opportunity of direct information if a substance is turned over 
by a certain enzyme, even in a low amount. As enzymes can be inhibited or induced by 
another drug or food, their activity can be influenced through genetic variations and 
interactions might occur. Poor and ultrarapid metabolizers gained interest in the efficacy 
and toxicity of pharmaceutical drugs such as codeine or tamoxifen.27,28 CYPs often 
involved in xenobiotic metabolism should be tested, like CYP1A2, CYP2A6, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4.22 To avoid over-estimation of 
that involvement, a correction can be calculated as will be described in the kinetic 
chapter. 
Phase II metabolism follows functionalization if necessary. Conjugation with large 
hydrophilic molecules such as glucuronic acid or sulfates leads to improved crossing 
urine or bile passage. Either water solubility is enhanced by this step or pH-dependent 
ionization prevents reabsorption.22 Uridine diphosphate glucuronyltransferases catalyze 
the transfer of glucuronic acid to form glucuronides while sulfotransferases transform a 
sulfonate moiety to sulfate conjugates. These two enzyme groups represent the most 
important ones for the phase II metabolism of xenobiotics. Furthermore, catechol-O-
methyltransferase (COMT) is a well-known enzyme from endogenous metabolism of 
neurotransmitters, leading to pharmacologically inactive compounds by methylation of 
hydroxy groups. This methylation prevents the binding to the respective receptors. 
According to the chemical structure, every compound with a similar catechol structure 
might be substrate of this enzyme as shown for e.g. 3,4-
methylenedioxymethamphetamine.29,30  
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Investigating drug metabolism can be performed using in vitro or in vivo studies. In vitro 
assays can be conducted in two different ways: on the one hand, cell systems like S9 or 
human hepatocytes can be used to simulate general phase I or even phase II 
metabolism of a specific compound. Details on involved enzymes can be evaluated by 
using single human expressed isozymes for their involvement.24,31-35 Even with these 
applicable systems, in vivo approaches are still necessary. They provide useful 
information not only on metabolizing steps, but also on absorption, distribution, and 
excretion.22 In vitro-in vivo correlations can be conducted for confirmation of cell system 
results in animal studies.36 
For lefetamine and its derivatives (Fig.1 a-c), neither in vitro nor in vivo metabolism 
studies have been published up to now. For diphenidine (Fig. 1d), small insights in 
metabolism were described by Wasaki et al. in consequence of intoxications.12 
Hydroxylations were the detected steps: mono-hydroxylation at the phenyl and at the 
piperidine moiety, combination of both steps and a bis-hydroxylation followed by 
dehydrogenation. All metabolites were detectable in urine and blood. Other phase I or 
phase II metabolites were not mentioned. In this study also quantitation was performed, 
which provided the following results: In blood and urine, both the parent compound was 
most abundant; mono-hydroxylation at the piperidine moiety was shown to be the most 
prominent metabolizing step. According to the lack of information, the elucidation by 
systematic metabolism studies for the diphenylethylamines was needed. 
 
1.1.4 Kinetic Studies of Diphenylethylamines 
The overall effectiveness of a certain enzyme to metabolize a drug depends on two 
aspects, the affinity to the enzyme and the enzyme capacity. The affinity of a drug to the 
enzyme is reported by the Michaelis-Menten-constant Km. It is defined as the substrate 
concentration that leads to half maximum turnover velocity. With νmax, the capacity, the 
maximal velocity of a turnover activity is described. Within the linear range of time and 
protein concentration, the formation rate is maximal resulting in constant metabolite 
formation independent of the substrate concentration. The product formation is 
measured, and with reference standards, the concentration of formed metabolites can 
be calculated. Using Michaelis-Menten equation (eq. 1), the kinetic parameters and 
profile are defined as: 
ν = (νmax * [S]) / (Km + [S])    (1) 
6 
The Km and νmax values of single isozymes can be compared to each other, also after 
inhibition. To avoid overestimation and to account for their distribution in human liver, a 
relative activity factor approach should be conducted using human liver microsomes 
(HLM).37 
 
1.1.5 Synthesis of Lefetamine 
Lefetamine is part of schedule I of the Narcotics Law in Germany, the synthesis, habit 
and sale are prohibited. As it was not commercially available, it had to be synthesized in 
a modified version of Eschweiler-Clarke via bis-methylation of the primary amine 
(DPEA).38 Using column chromatography for separation and purification, identity was 
checked and yield was calculated using liquid-chromatography (LC)-high resolution 
(HR)-mass spectrometry (MS) and NMR.36 This substance was then used for the 
metabolism and kinetic studies in vitro and in vivo. 
 
1.1.6 Detection, Structure Elucidation, and Quantification in Body Fluids 
There are different ways to elucidate the chemical structure of compounds. MS can be 
used for structure elucidation over a wide mass to charge ratio. According to classic 
fragmentation rules, it can be done via the recorded spectra. This is especially true for 
HR-MS as it provides the possibility to measure the accurate (fragment) mass and 
propose the elemental composition of compounds or fragments. However, as 
fragmentation spectra may not provide detailed information of molecule, NMR could be 
conducted to confirm proposed structures by MS but also to provide additional 
information on exact positions.  
According to the high sensitivity of MS, hyphenated techniques such as gas-
chromatography (GC)-MS or LC-MS are well established methods in clinical and 
forensic laboratories. For detection and unambiguous identification, several reference 
libraries were available.39-43 Using these, the analysis of samples can be done nearly 
automated as library search can be integrated in workflows.44,45 Urine is easy to access 
and concentrated by a factor of about ten compared to blood, which makes it to the 
preferred matrix to use. Some analytes are metabolized to such an extent that it is 
difficult to detect them in their unchanged form in urine.46-48 While urine provides an 
extended detection window for xenobiotics, blood, plasma, and serum samples are 
often used to access the presence and concentration, which might explain the 
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pharmacological effects. Plasma is cleared from parent compounds rather fast, either by 
metabolization or redistribution into fat tissues, metabolites might be excreted in urine 
over days up to weeks.49-53 If only screened for the unchanged xenobiotic in the sample, 
false negative results might be produced.42,54-57 In these cases, knowledge of 
metabolites is mandatory for toxicological analysis. Therefore, the metabolites detected 
in the studies for this dissertation, were included in the unique metabolite based 
reference libraries.58-60 
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2. Aims and Scopes 
1,2-Diphenylethylamines have been synthesized and tested for their pharmacological 
activity soon after the effects of phenethylamines were known. Several years after 
marketing lefetamine (N,N-dimethyl-1,2-diphenylethylamine), the substance has 
become controlled. Lately, chemical derivatives of it were confiscated by the police in 
Germany, but no detailed information concerning these compounds was available. In 
Japan and Sweden, another derivative, namely diphenidine, was part of fatal 
intoxications, which already led to studies. As the abuse of designer drugs is relevant in 
clinical or forensic cases, parameters like metabolism, detectability and kinetics should 
be studied using common techniques in order to ensure their interpretation of toxicity. 
These aims and scopes were realized by: 
 
 Studies on the metabolism and detectability of lefetamine-derived 1,2-
diphenylethylamines using GC-MS, LC-MSn, and LC-HR-MS/MS 
 
 Synthesis of lefetamine, the pharmaceutical lead of diphenylethylamines, and 
confirmation of it by NMR 
 
 Studies on the metabolism, confirmation of the proposed phase I metabolites 
using human liver preparations, and detectability of lefetamine using GC-MS, LC-MSn, 
and LC-HR-MS/MS 
 
 Investigation of toxicokinetic parameters regarding the initial metabolites of 
lefetamine and its derived derivatives  
 
 Studies on the metabolism, confirmation of the proposed phase I metabolites 
detected in rat urine using human liver preparations, and detectability of diphenidine 
using GC-MS, LC-MSn, and LC-HR-MSn 
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3. Publication of the results 
The results of the studies were published in the following papers: 
 
3.1 Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine 
(NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): Metabolism 
and detectability in rat urine using GC-MS, LC-MSn and LC-high resolution 
(HR)-MS/MS61 (DOI 10.1002/dta.1621) 
10 
11 
3.2 Lefetamine, a controlled drug and pharmaceutical lead of new 
designer drugs: Synthesis, metabolism, and detectability in urine and 
human liver preparations using GC-MS, LC-MSn, and LC-high resolution-
MS/MS36 (DOI 10.1007/s00216-014-8414-3) 
12 
13 
3.3 Toxicokinetics of lefetamine and derived diphenylethylamine 
designer drugs – Contribution of human cytochrome P450 isozymes to 
their main phase I metabolic steps62 (DOI 10.1016/j.toxlet.2015.08.012) 
14 
15 
3.4 Diphenidine, a new psychoactive substance: Metabolic fate 
elucidated with rat urine and human liver preparations and detectability 
in urine using GC-MS, LC-MSn, and LC-HR-MSn63 (DOI 10.1002/dta.1946) 
16 
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4. Conclusions 
NEDPA and NPDPA, the two lefetamine-derived designer drugs, were shown to be 
extensively metabolized in rats. After application of a high dosage of the drugs, N-
dealkylation, mono- and bis-hydroxylation of the benzyl-ring, combination of those steps 
and also the combined N-dealkylation and hydroxylation of the phenyl moiety were for 
both drugs the proposed phase I metabolism steps. As conjugated compounds, 
glucuronides and sulfates of the hydroxy and hydroxy-methoxy metabolites could be 
detected. No case reports of abuse have been known, so the dosage for the studies of 
detectability using standard urine screening approaches (SUSA) of the author’s lab was 
scaled-up from the medically used lefetamine (Santenol).58,60,64 In the rat urine, 
collected for 24 hours, N-dealkyl, N-dealkyl-hydroxy, and hydroxy metabolites were 
detectable by GC-MS SUSA. Using LC-MSn SUSA, NEDPA intake was revealed by the 
glucuronides of mono- and bis-hydroxy, N-deethyl-hydroxy and hydroxy-methoxy 
metabolite, for NPDPA only by hydroxy glucuronide. Some interesting aspects came up 
while studying these derivatives: first, GC-MS fragmentation provided an alpha-
cleavage, so hydroxylation at phenyl- or at benzyl-moiety was definable. In contrast, in 
LC-MS (electrospray ionization) the loss of the nitrogen part was the initial 
fragmentation step. Thus, the daughter spectra of corresponding hydroxy metabolites 
(at phenyl and benzyl moiety) obtained at different retention times, were identical. All 
GC-MS proposed metabolites could be confirmed by LC-HR-MS/MS, and additionally 
glucuronides and sulfates which are not detectable by GC-MS. The second important 
point is that there are common metabolites after consumption of NEDPA, NPDPA, 
lefetamine, or diphenidine, namely those after N-dealkylation. But the detectability 
studies presented at least one unique metabolite, so the differentiation after intake of 
one of those applied drugs should be possible.61 
After the urgent studies on the confiscated drugs NEDPA and NPDPA, still no 
information of the metabolism or detectability of the pharmaceutical lead lefetamine has 
been known. It is scheduled in the narcotics act because of its known effects, but not 
commercially available as reference standard. With permission, it was synthesized via 
bis-methylation starting with DPEA, which is legally available. After isolation and 
purification, synthesized lefetamine was qualitatively and quantitatively characterized by 
LC-HR-MS and NMR, so it could be used for in vitro and in vivo metabolism studies and 
for determination of enzyme kinetic profiles. After application of a 25 mg/kg BW dose of 
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lefetamine to rats, urine was collected over 24 hours and analyzed by GC-MS and LC-
HR-MS/MS. The following metabolizing steps could be detected: N-oxidation, mono- 
and bis-N-dealkylation, mono- and bis-hydroxylation at various positions of the aryl 
moieties, combinations of those steps, glucuronidation, sulfation, and methylation of one 
of the hydroxy-groups by COMT. In summary, the metabolic pathways already 
investigated for NEDPA and NPDPA could also be found for lefetamine. The proposed 
N-oxide, N-demethyl, N,N-bis-demethyl, N-demethyl-hydroxy, and hydroxy metabolites 
of rat urine studies were confirmed in HLM, the dealkylated metabolites also in human 
liver cytosol (HLC). For the study of detectability, the applied dosage of lefetamine was 
scaled-up as already described for the derivatives. Besides N,N-bis-demethyl, N,N-bis-
demethyl-hydroxy, N-demethyl-hydroxy, N-demethyl-bis-hydroxy and its corresponding 
glucuronide, lefetamine itself was detectable in rat urine. So in case of co-consumption 
of lefetamine as controlled substance and one of its “legal high” derivatives, 
differentiation should be possible. As mentioned before, all metabolite spectra have 
been implemented into existing metabolite-based GC-MS and LC-MS libraries to 
enhance the detectability and to allow differentiation of applied drugs.36,58-60 
As drugs are often co-consumed with medication or other drugs, interactions (e.g. for 
biotransformations of these) might occur. Therefore, the involvement of the ten most 
important CYPs in the initial N-dealkylation was determined.62 The three drugs NEDPA, 
NPDPA, and lefetamine were incubated with baculovirus-infected insect cell 
microsomes of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, 
CYP2E1, CYP3A4, and CYP3A5. CYP1A2, CYP2B6, CYP2C19, CYP2D6, and 
CYP3A4 were capable of forming the initial metabolite of lefetamine and NEDPA, for 
NPDPA the formation of its metabolite by CYP2D6 was too low to achieve. After the 
development of a quantitative method, kinetic profiles of metabolite formation were 
investigated and found to follow classic Michaelis-Menten kinetics with Km between 2 
and 331 µM and νmax between 4 and 36 pmol/min/pmol CYP450 enzyme. With 
application of the relative activity factor (RAF) approach to avoid overestimation of those 
parameters, the contribution of a single isozyme in the whole cell compartment of HLM 
was calculated.34 Net clearances were about 72% by CYP 2B6, 17% by CYP3A4 and 
less than 10% for CYP1A2, CYYP2C19, and CYP2D6 for lefetamine. For 
NEDPA/NPDPA the percentage of net clearance was calculated as 27/18 %, 30/24 %, 
23/28 %, and 17/30 % for CYP1A2, CYP2B6, CYP2C19, and CYP3A4, respectively and 
for NEDPA additionally by 2D6 by 4%. Chemical inhibition was in line with in vivo 
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contributions. As there are at least four CYP isozymes involved in one initial step of 
metabolism, there should be a low clinical relevance of interactions. However, individual 
polymorphism in CYPs, other drugs and food contents co-consumed, and the 
endogenous transporters may increase the risk of clinical relevant interactions. This 
could only be estimated by further studies or evaluated from case reports. 
The last studied diphenylethylamine was also confiscated by the German police. After 
identity was confirmed to be diphenidine by HR-MS and NMR and purity was quantified 
by qNMR, studies on metabolism in rat and human liver preparations were conducted. 
Mono- and bis-hydroxylation at aryl and also at piperidine moiety, followed by 
dehydrogenation of the hydroxy-piperidine to an oxo-metabolite, were the one-step 
metabolites detected. N-dealkylation and combinations of it with hydroxylation were the 
additional reactions for phase I metabolism. Glucuronides and hydroxy-methoxy 
compounds turned over by COMT represented the conjugated phase II metabolites. 
Fragmentation was comparable to already studied 1,2-diphenylethylamines: An alpha-
cleavage from nitrogen in GC-MS allowed the differentiation of hydroxylation at the aryl 
or at the piperidine ring. The metabolites after N-dealkylation were the same as those of 
lefetamine, NEDPA and NPDPA, so comparable with the underlying spectra of MS 
libraries. All the GC-MS detected metabolites could be confirmed using LC-HR-MSn. 
The initial, oxygenated metabolites in rat urine were also built in HLM and HLC. To fulfill 
metabolic elucidation and predict interaction, a CYP assay was passed. CYP1A2, 
CYP2B6, CYP2C19, and CYP3A4 formed hydroxy-aryl, hydroxy-piperidine, and bis-
hydroxy-piperidine metabolites, while CYP2D6 was only involved in the turnover to 
mono-hydroxy metabolites. With this knowledge of metabolism, urinalysis for 
detectability was conducted afterwards with doses scaled up from case reports of 
Japan. Several metabolites were detected using the different SUSA: by GC-MS: the oxo 
(so the dehydrogenated hydroxy-piperidine part), hydroxy-piperidine, oxo-hydroxy-
phenyl, two hydroxy-phenyl-hydroxy-piperidine, and N-dealkyl-hydroxy-methoxy 
metabolites; and by LC-MSn: oxo, hydroxy-aryl, and bis-hydroxy-piperidine for phase I 
and for phase II hydroxy-methoxy and the glucuronides of hydroxy-methoxy and mono-
hydroxy-aryl metabolites. 
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5. Summary 
In the presented studies, metabolism and detectability were investigated of designer 
drugs belonging to the class of 1,2-diphenylethylamines. NEDPA, NPDPA, and 
diphenidine were confiscated drugs, while lefetamine had to be synthesized first. The 
identity and purity of the drugs were at first confirmed by HR-MS and NMR studies. 
Common phase I metabolic pathways of NEDPA, NPDPA, lefetamine and diphenidine 
were N-dealkylation, mono- and bis-hydroxylation at ring moieties, combination of both 
steps. Additionally, lefetamine and diphenidine were N-oxidized. Glucuronidation and 
catechol methylation for phase II metabolism were shown for all substances, for 
NEDPA, NPDPA, and lefetamine, but sulfates only for NEDPA, NPDPA, and lefetamine. 
In detectability studies, each drug intake resulted in common but also specific 
metabolites allowing detection and differentiation of the four tested compounds. The 
initial phase I metabolites detected in rat urine could mostly be confirmed in HLM. 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CP2D6, and CYP3A4 were the enzymes 
mainly involved the initial metabolic steps of 1,2-diphenylethylamines. For NEDPA, 
NPDPA, and lefetamine also enzymatic turnover was elucidated, which showed that 
they all followed classic Michaelis-Menten kinetics. 
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7. Abbreviations 
 
cDNA copy deoxyribonucleic acid 
CNS central nervous system 
COMT catechol-O-methyltransferase 
CYP cytochrome P450 
DPEA 1,2-Diphenyethylamine 
e.g. exempli gratia, for example 
GC gas chromatography 
HLC human liver cytosol 
HLM human liver microsomes 
HR high resolution 
LC liquid chromatography 
L-SPA Lefetamine 
MALDI matrix assisted laser desorption ionization 
MAO monoamineoxidase 
MDMA 3,4-methylenedioxymethamphetamine 
MS mass spectrometry 
NEDPA N-ethyl-1,2-diphenylethylamine 
NMDA N-methyl-D-aspartate 
NMR nuclear magnetic resonance spectroscopy 
NPDPA N-iso-propyl-1,2-diphenylethylamine 
SUSA Standard urine screening approach(es) 
UN United Nations 
WHO World Health Organization 
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8. Zusammenfassung 
In den hier vorgestellten Studien wurden der Metabolismus und die Nachweisbarkeit 
von vier Designerdrogen aus der Klasse der 1,2-Diphenylethylamine untersucht. Dafür 
wurden konfisziertes NEDPA, NPDPA und Diphenidin eingesetzt, während Lefetamin 
zuerst synthetisiert werden musste. Die Identität und Reinheit der verwendeten Stoffe 
wurden unter anderem durch HR-MS und NMR belegt. Gemeinsame 
Metabolisierungsschritte von NEDPA, NPDPA, Lefetamin und Diphenidin waren die N-
Dealkylierung, Ein- und Zweifachhydroxylierung an den Ringstrukturen sowie die 
Kombination aus beiden Schritten. Zusätzlich wurden für Lefetamin und Diphenidin N-
Oxide nachgewiesen. Alle Substanzen zeigten ausgeprägten Phase II Metabolismus 
(Glukuronidierung und Catechol-Methylierung). Für NEDPA, NPDPA und Lefetamin 
konnten zusätzlich Sulfatkonjugate detektiert werden. Die Einnahme der vier Drogen 
konnte im Urin mittels gemeinsamer Metabolite nachgewiesen werden, spezifische 
erlaubten eine Unterscheidung. In vitro Experimente mit humanen Lebermikrosomen 
konnten die in vivo Resultate aus Rattenurin größtenteils bestätigen. CYP1A2, 
CYP2B6, CYP2C9, CYP2C19, CP2D6 und CYP3A4 waren hauptsächlich an der 
Umsetzung der 1,2-Diphenylethylamine beteiligt. Diese setzten NEDPA, NPDPA und 
Lefetamin nach klassischer Michaelis-Menten-Kinetik um. 
